CIELO: a randomized, double-blind, placebo-controlled, phase 3 basket study of satralizumab in patients with NMDAR- or LGI1-antibody encephalitis

Eitemau Tebyg

• Innovation and optimization in autoimmune encephalitis trials: the design and rationale for the Phase 3, randomized study of satralizumab in patients with NMDAR-IgG-antibody-positive or LGI1-IgG-antibody-positive autoimmune encephalitis (CIELO)
  gan: Lee, S, et al.
  Cyhoeddwyd: (2024)
• Innovation and optimization in autoimmune encephalitis trials: the design and rationale for the Phase 3, randomized study of satralizumab in patients with NMDAR-IgG-antibody-positive or LGI1-IgG-antibody-positive autoimmune encephalitis (CIELO)
  gan: Soon-Tae Lee, et al.
  Cyhoeddwyd: (2024-08-01)
• CSF Findings in Chinese Patients with NMDAR, LGI1 and GABABR Antibody-Associated Encephalitis
  gan: Qiao S, et al.
  Cyhoeddwyd: (2024-03-01)
• Comprehensive B-Cell Immune Repertoire Analysis of Anti-NMDAR Encephalitis and Anti-LGI1 Encephalitis
  gan: Jingjing Feng, et al.
  Cyhoeddwyd: (2021-10-01)
• Seizures and risk of epilepsy in anti‐NMDAR, anti‐LGI1, and anti‐GABABR encephalitis
  gan: Chun‐Hong Shen, et al.
  Cyhoeddwyd: (2020-08-01)